Aims: Baclofen has gained interest in treating alcohol use disorder patients. These patients are at risk of voluntary drug intoxications. Understanding the context of baclofen's widespread use for alcohol use disorder, a recent evaluation of the epidemiology, morbidity and mortality of baclofen self-poisoning episodes is necessary. Methods: All baclofen self-poisoning reported to the Western France Poison Control Centre between January 2008 and December 2015 were included for analysis in this retrospective study. Baclofen poisoning cases were compared to the 31,859 non-baclofen voluntary poisoning cases declared over the same period. Results: Number of baclofen poisoning grew from 8 cases in 2008 to 91 cases in 2015, attributable to patients purposely treated for alcohol use disorder. Overall, 190 cases were considered: 111 patients (59%) had Glasgow coma score (GCS) ≤12 at hospital admission and 77 had GCS > 12 (41%). Eighty patients required mechanical ventilation (42.6%). Neurological severity (GCS ≤ 12) was associated with seizures (n = 24, 22% vs. n = 2, 3%, P < 0.001). Two patients were deceased at first medical evaluation and three died in the hospital (mortality rate 2.6%). Non-baclofen cases had lower rate of endotracheal intubation (n = 1833, 6%, P < 0.001) and mortality rate (n = 299, 0.1%, P = 0.02). Conclusions: Baclofen self-poisoning cases has risen in recent years due to baclofen intake for alcohol use disorder therapies. The risk-benefit ratio may be evaluated before baclofen is safely prescribed.
INTRODUCTION
Baclofen, a derivative of γ-aminobutyric acid, is a selective agonist of the gamma-aminobutyric acid (GABA) B receptor the activation of which may reduce dopamine release and N-methyl-D-aspartate transmission (Imbert et al., 2015) . It has been originally used to treat central spasticity (Hudgson and Weightman, 1971 ), but has recently been considered and evaluated to treat alcohol use disorder (and more specifically alcohol dependence) albeit with mixed results (Addolorato et al., 2007 (Addolorato et al., , 2011 Garbutt et al., 2010; Müller et al., 2015; Beraha et al., 2016; Reynaud et al., 2017) . Its use spread widely over recent years in France (Rolland et al., 2012; Rigal et al., 2015; Simioni et al., 2016) . A report of French baclofen prescriptions, between 2009 and 2015, has been published: baclofen intake (except for neurological conditions) has concerned 200,000 people, the drug has often been delivered beyond the prescription conditions, and the efficacy of high-dose baclofen to treat alcohol dependence is still unclear (ANSM, 2017) . Furthermore, the safety profile is alarming with an increase of hospitalization and mortality (specifically for highdose regimen) (ANSM, 2017) . In light of those results, the ANSM (French National Agency for Medicines and Health Products Safety) has made a commitment to adjust the special conditions of baclofen prescriptions to treat alcohol dependence.
Patients suffering from alcohol use disorder have an increased frequency of psychiatric diseases including mood disorders, and are at high risk of attempting suicide, particularly by drug overdose (Flensborg-Madsen et al., 2009; Boenisch et al., 2010; Dore et al., 2011) . Thus, evaluation of the benefit/risk balance of a new treatment in this population requires special attention of acute toxicity by self-poisoning. Baclofen as treatment for alcohol use disorder is often prescribed in doses higher than for its classical spasticity indication (>30 mg/d), making it possible for massive drug overdose because of easier drug availability.
Baclofen acute toxicity has been reported in small series of patients suffering spasticity, showing neurological toxicity (Paulson, 1976; Lee et al., 1992; Franchitto et al., 2013) . Besides, baclofeninduced sedation seems to be dose-related (Rolland et al., 2015) . The aim of this study is to describe the epidemiology, morbidity and mortality of baclofen self-poisoning episodes in the context of its widespread use for alcohol use disorder.
MATERIALS AND METHODS
This retrospective observational study was based on the phone declarations from all emergency departments and intensive care units of Western France (representing a population of more than 12 million people and 50 university or general hospitals) to the Poison Control Centre (PCC) of the Angers University Hospital, Angers, France. All suspected cases of baclofen self-poisoning, without any exclusion criteria, either in isolation or in combination with other toxicants, from 1 January 2008 to 31 December 2015 were included. The Angers University Hospital ethics committee approved this study and waived the need for patient consent (approval number: 2015-89) .
Data analyzed
The following data were collected from PCC files and from medical reports from the hospitals where patients had been admitted for the self-poisoning: demographic data: age, gender, weight, past medical history of alcohol use disorder (as diagnosed and noted in medical files) and psychiatric diseases (as defined by a follow-up by a psychiatrist or antidepressant or neuroleptic drug in usual treatment), indication for baclofen therapy (spasticity, alcohol use disorder, treatment of a relative), previous suicide attempt(s); self-poisoning characteristics: baclofen supposed ingested dose (SID), drug(s) co-ingested, baclofen blood concentration(s). Besides, other data were gathered: self-poisoning acute manifestations and outcome: Glasgow coma score (GCS) at hospital admission, presence of delirium requiring sedative agents, seizures, electrocardiographic (EKG) abnormalities, acute kidney injury, electroencephalographic (EEG) abnormalities, aspiration pneumonitis. Some last characteristics were collected concerning organ support requirement and outcome: mechanical ventilation, renal replacement therapy (RRT), vasopressor use, intensive care unit (ICU) and hospital length of stay, hospital mortality. In addition, SAPSII (Simplified Acute Physiology Score) and SOFA (Sequential Organ Failure Assessment) scores (Le Gall et al., 1993; Vincent et al., 1996) , known to assess patient's status during their stay in ICU, were extracted from medical files in ICU patients. The role of baclofen in the death of patients was evaluated by the French calculation method of imputability in toxicovigilance (version 7.6). It is a five-step scale (null, not excluded, possible, probable and highly probable) based on clinical, paraclinical, circumstances and bibliometric criteria (Comité de Coordination de la Toxicovigilance, 2015).
Control group
Hospital mortality and requirement for mechanical ventilation in baclofen self-poisoning patients were compared with the 31,859 non-baclofen self-poisoning episodes reported to the PCC of Angers University Hospital, between 2008 and 2015.
Statistical analyses
Baclofen self-poisoning patients were divided into two groups according to nadir GCS (we consider coma as the more relevant sign of baclofen intoxication). Patients with GCS ≤ 12 constituted the severe intoxication group and patients with GCS > 12 constituted the non-severe intoxication group. This threshold was set using the poison severity score, a standardized scale for grading the severity of poisoning (it corresponds to the transition from minor to moderate symptoms based on the nervous system) (Persson et al., 1998) .
Data were presented as median (interquartile range or minimum and maximum values) or n (%) as appropriate. Between-group comparisons were performed using Chi 2 -test for categorical data, Mann-Whitney test for continuous data. The Spearman correlation test was used between-group comparisons for continuous data. Missing data were excluded from analysis. A value of P < 0.05 was considered statistically significant. In a second step, analysis with Chi 2 -tests were performed to compare hospital mortality and requirement for mechanical ventilation, between baclofen self-poisonings and non-baclofen self-poisoning episodes.
RESULTS
Baclofen self-poisoning reported to PCC increased by an 11.3 factor from 2008 to 2015 due to a major increase of patients taking baclofen for alcohol use disorder (Fig. 1) . Overall, 190 episodes of self-poisoning from 190 patients were included for analysis. Among these, two deaths were diagnosed at home at first medical evaluation by emergency services. Among the 188 remaining patients, 111 patients (59%) had GCS ≤ 12 at the first medical assessment, and 77 patients (41%) had GCS > 12. There is no significant difference regarding the rate of combined drug intoxication between the two groups. Demographic data and self-poisoning characteristics of the severe and non-severe groups are given in Table 1 . Patients in the severe group had more frequent alcohol use disorder at the limit of statistical significance. Although past histories of psychiatric diseases were extremely frequent in both groups, severe intoxications were significantly associated with follow-ups for mood disorders (57 vs. 36%, with P < 0.01).
Patients with severe self-poisoning had a higher suspected ingested dose (P < 0.001) and were frequently admitted to the ICU and ventilated. SAPSII score and SOFA score in ICU-admitted patients were 44.5 (36-58) and 5 (4-7), respectively. Patients with severe intoxication had more frequent seizures (P < 0.001).
Delirium requiring sedative agents was frequent but not significantly different between the two groups. EKG was rarely performed in non-severe intoxications; in severe self-poisonings 12 out of 96 (13%) patients with EKG performed showed mild QT prolongation, as notified in the medical reports (co-ingestion of other toxicant may have played a role in six patients). Of note EEG was performed in 25 ICU patients and showed burst suppression in 12 (without associated use of therapeutic sedation). Baclofen blood concentration was rarely measured and was significantly higher in severe intoxications. Renal replacement therapy (RRT) was performed in 12 ICU patients. Indication for RRT was acute kidney injury in four patients. In the remaining eight patients RRT was started solely for baclofen blood purification in the absence of any significant renal impairment.
In comparison to non-baclofen self-poisoning episodes declared to the PCC of Angers on the 2008-2015 period, baclofen selfpoisoning was associated with a more frequent requirement for mechanical ventilation (1833/31,859 (5.7%) vs. 80/188 (42.6%), respectively, P < 0.001) and a higher frequency of death (299/ 31,859 (0.1%) vs. 5/190 (2.6%), respectively, P = 0.02).
Of the 5 deceased, cause of death was related to a cardiac arrest at first medical evaluation for three cases (post-mortem blood analysis), including one patient initially resuscitated but who eventually died of post-anoxic encephalopathy. One patient had seizures symptomatic of anoxic brain injury resulting in a withdrawal of life support. One patient had an in-ICU late hypoxic cardiac arrest occurring in a context of critical illness polyneuromyopathy. Accountability of baclofen in these patients could be qualified as possible or highly probable for three and two patients, respectively. 
DISCUSSION
This retrospective study collecting data from a poison centre covering a large portion of the French territory and French population (20%) showed a more than 11-fold increase in the number of baclofen self-poisoning episodes over recent years. As stated in the indication found in PCC data and hospital medical files, this increase was related mainly to prescription for alcohol use disorder. Delirium and seizures were frequently observed. Baclofen self-poisoning was characterized by a high frequency of mechanical ventilation (42.6%) and death (2.6%), with more than a 7-fold and 26-fold excess, respectively, in comparison to non-baclofen poisoning. A near tripling from 2009 to 2015 of sales of baclofen has been reported in France, with the expansion of patients treated (exclusive of prescriptions for neurological conditions) (ANSM, 2017) . Thus, the increase in self-poisoning exceeded what could be expected from this figure. Awareness of baclofen changing indications may have lead practitioners to report more frequently cases of selfpoisoning but this is unlikely to solely explain the observed major increase. Of note, this increase is not universal, as the Danish nationwide register-based survey, showed no increase of baclofen intoxication despite increased sales, nevertheless the authors have suspected a potential underreporting of baclofen poisonings in Denmark (Kiel et al., 2015) . Furthermore, to our knowledge, the Danish national authority has not specified conditions of baclofen prescription for alcohol use disorder, which compromises the comparison with our results.
Alcohol dependence is frequently associated with psychiatric disorders (Grant et al., 2004) and a high level of impulsivity (Rupp et al., 2016) . All these conditions enhance the risk of suicide. In addition, it has been shown that high-dose baclofen intake can stimulate impulsivity, trigger aggressive behaviour and as a consequence increase the suicidal risk through activation of the mesolimbic dopamine system (Cruz et al., 2004; Takahashi et al., 2012) . Finally, the association between mood disorders and the acute severity of selfpoisoning observed in this study has already been reported in the literature, evidencing a potential link between the intensity of the desire to die and toxicant ingested dose (Baer et al., 2016) . Considering all these data together, prescribing baclofen in patients with alcohol use disorder may induce a deleterious association leading to frequent and severe intoxications. However, this should be balanced with the potential reduction in mortality and morbidity due to alcohol use disorder cessation if proven in pending studies, with appropriate psychiatric supervision (especially when patients are suffering from psychiatric disorders).
There are several reports on the frequency and severity of baclofen-induced encephalopathy with delirium, seizures, burst suppression on the EEG and leading to mechanical ventilation, aspiration pneumonitis and eventually death (Sullivan et al., 2012; Pommier et al., 2014; Kiel et al., 2015) . Rate of intubation and mechanical ventilation has been reported from 30 to 50% in these studies, which is a strong marker of the frequent severity intoxication. Our results, being one of the largest series to our knowledge, confirm and extend all these data in the era of baclofen prescription for alcohol use disorder (Dupouy et al., 2014) . Importantly, being poison centre-based and not hospital-based, our study allowed for consideration of deaths occurring at home. This was not the case in previous studies that reported a lower frequency of fatal outcome, missing a major aspect of the clinical picture (Ghose et al., 1980; Dupouy et al., 2014; Pommier et al., 2014; Kiel et al., 2015) . This issue has also been highlighted by previous national reports to French PCCs, during 2008 and 2013 (Pelissier et al., 2017 .
Several characteristics discriminated between severe and nonsevere cases. Seizures were mainly observed in the most severe cases with altered consciousness. Baclofen is a known proconvulsivant drug, which increases neural excitation in some parts of the brain (Fujita et al., 2011) , and patients with alcohol use disorder may easily suffer from seizures (lower seizure threshold). Conversely, delirium was observed equally across severe and non-severe cases. One may wonder whether delirium is related to alcohol withdrawal or to baclofen, which cannot be determined from our dataset. Factors influencing vulnerability from baclofen-withdrawal delirium include duration of exposure to the medication and the abruptness of baclofen cessation (Richter et al., 2016) . Regrettably, we have no information concerning alcohol consumption before self-poisoning, which could have permitted us to deduce the contribution of alcohol withdrawal. Furthermore, among all our intoxication cases, none of them had been treated early during their hospital stay with baclofen, to prevent an associated baclofen withdrawal. Though, independently of alcohol withdrawal syndrome, further data are necessary to highlight the role of baclofen withdrawal syndrome in every unexplained case of confusion, agitation or hallucination.
One significant point concerning the more severe cases is the fact that the median suspected ingested dose (400 mg) is modestly superior to the upper range of prescribed daily dose in one trial (270 mg) (Müller et al., 2015) . Such high doses, can indeed be well tolerated thanks to a titration phase of several weeks (Müller et al., 2015) . However, our study shows that the theoretical difference between therapeutic and toxic doses is very close and that the titration phase is of utmost importance. In this study, baclofen blood concentrations were done more frequently in patients with severe self-poisoning (30%). Regretfully, in most poisoning cases with baclofen blood level, the blood collection was sampled at different times during the hospital stay, which prevents us from comparing them with each other.
Use of dialysis was relatively frequent, notably in patients without renal impairment. It reflects the debate on its usefulness in baclofen poisoning (Mégarbane et al., 2016) . Our data did not permit analysis of the clinical impact of this technique.
Several factors limit the interpretation of our results. Declarations to poison centres are dependent on the physician making this decision and may favour declarations in more severe cases. Co-ingestion of multiple drugs was frequent and it was impossible to discriminate the respective role of the different drugs ingested concomitantly. One major point is the lack of information concerning the non-baclofen intoxications which restrains the use of a multivariable logistic regression model (between baclofen and non-baclofen selfpoisonings), to control for confounding parameters. In the absence of such analysis, we only rely on extrapolations that should be taken with caution.
The present study did not allow for long-term follow-up. Indeed, it has been shown that patients after suicide attempts have prolonged increased risk of death from various causes (Pompili et al., 2010; Baer et al., 2016) . Unfortunately, it was impossible to obtain the exact number of patients treated for alcohol abuse with baclofen over the study period in the same region. This could have permitted us to describe accurately the increased risk of self-poisoning in this population.
Finally, besides the risks, the benefits of baclofen to treat alcohol dependence are discussed in the recent results of the ALPADIR study (Reynaud et al., 2017) . Even if, a tendency towards a reduction in alcohol consumption and a significant decrease in cravings are observed in favour of baclofen, this study does not demonstrate the superiority of baclofen in the maintenance of abstinence at the target dose (180 mg/d).
CONCLUSIONS
Baclofen self-poisoning increased tremendously over recent years due to an increase in the drug being prescribed for alcohol use disorder. Baclofen self-poisoning was characterized by encephalopathy with consciousness alteration, seizures and delirium frequently requiring mechanical ventilation. Beyond the supposed benefits of baclofen to treat alcohol dependence, the associated morbidity and mortality, are a concern to be considered when prescribing this drug to a patient at risk of suicide. Alcohol dependence is frequently associated with psychiatric disorders; consequently, before every prescription, a psychiatric history must be investigated to discuss the risk-benefit ratio of baclofen therapy, and organize an appropriate psychiatric follow-up.
